Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-AF: Safety of Fondaparinux in electrical cardioversion of atrial fibrillation
2008-000789-22Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2009
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of fondaparinux in Atrial fibrillation (AFib) (2 arms), sponsored by GSK. Primary endpoint: Primary combined efficacy/safety endpoint. Started Apr 2009; status: completed.
02
Drugs
fondaparinux
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2008-000789-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000789-22.